Lipid signal turns off macrophage TB defenses

Tuberculosis remains a global health challenge because Mycobacterium tuberculosis has clever ways to evade the immune system and persist in the body. A key front line of defense is the macrophage, a white blood cell that engulfs and destroys bacteria. Yet researchers do not fully understand how M. tuberculosis reorganizes macrophage metabolism to blunt these defenses. To study this directly in a human clinical context, Luciana Balboa and colleagues turned to tuberculous pleural effusion (TB-PE), a fluid that accumulates around the lungs in many TB patients and provides a window into the infection microenvironment. Working with patient-derived TB-PE samples, the team exposed human macrophages to components of this fluid and watched how their metabolism and microbe-killing activity changed. The experiments revealed that something in the TB-PE alters macrophage metabolism in a way that leaves them less able to control M. tuberculosis. By focusing on this clinically relevant fluid, the researchers could link changes in host metabolism to impaired antimicrobial function in a setting directly connected to human disease.

To pinpoint what in TB-PE was responsible, the researchers used lipidomic analysis of patient samples and found an enrichment of the specialized pro-resolving mediator Resolvin D5 (RvD5). They showed that RvD5 signals through the receptor GPR32 to suppress macrophage microbicidal activity. Importantly, the acellular fraction of TPE was sufficient to induce RvD5 secretion by monocytes, and pleural monocytes from TB patients showed increased expression of RvD5 biosynthetic enzymes, supporting local production. On the metabolic level, RvD5-GPR32 signaling inhibited glycolysis in macrophages without promoting oxidative phosphorylation, and this change reduced HIF-1α activity. Reduced HIF-1α correlated with poorer intracellular M. tuberculosis control. Crucially, when HIF-1α was stabilized, antimicrobial function was restored, linking the lipid signal to a specific metabolic and transcriptional pathway that controls bacterial killing.

These findings identify a clear molecular axis—RvD5 acting through GPR32 to suppress HIF-1α-dependent metabolism—as a mechanism by which the TB microenvironment can disarm macrophages. By showing that a lipid mediator enriched in TB-PE rewires macrophage energy use and weakens intracellular control of M. tuberculosis, the study points to new directions for host-directed TB therapy. Interventions that prevent RvD5-GPR32 signaling, that limit local production of RvD5, or that restore HIF-1α activity in macrophages could potentially revive antimicrobial metabolism and improve bacterial clearance. Beyond therapeutic ideas, the work also highlights the value of studying patient-derived TB-PE as a clinically relevant immunometabolic window; the fluid contains signals that would be missed in simpler laboratory models. Overall, the RvD5-GPR32-HIF-1α axis represents both a mechanistic insight into TB immune evasion and a potential target for treatments aimed at boosting the host response.